The state of Maryland currently has 4 active clinical trials seeking participants for Primary Biliary Cholangitis research studies. These trials are conducted in various cities, including Baltimore, Bethesda, Rockville and Annapolis.
IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
Recruiting
To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/18/2025
Locations: Mercy Medical Center - Baltimore, Maryland, Baltimore, Maryland
Conditions: Primary Biliary Cholangitis
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Recruiting
To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Mercy Medical Center, Baltimore, Maryland +1 locations
Conditions: Primary Biliary Cholangitis
Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.
Recruiting
Study to investigate the efficacy and safety of two doses of K-808 (pemafribate) in subjects with PBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: Mercy Medical Center - Mcauley Plaza, Baltimore, Maryland
Conditions: Primary Biliary Cholangitis
An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Recruiting
The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/11/2024
Locations: Mercy Medical Center, Baltimore, Maryland
Conditions: Primary Biliary Cholangitis, Compensated Cirrhosis, Hepatic Impairment